

People Living with CLL Deserve More


Understanding the Unmet Need in CLL

In order to better understand the unmet need in CLL and the urgency for alternative and later-line treatment options, Lilly surveyed people living with the disease, their caregivers and the health care providers (HCPs) who treat them.

Many people living with this form of leukemia report feeling satisfied with their current treatment. Yet, most people living with CLL say side effects from their treatment have a significant impact on their quality of life and many express concerns should their current treatments stop working.

What is Chronic Lymphocytic Leukemia (CLL)?

CLL is typically a slow-growing blood cancer that starts from white blood cells in the bone marrow, known as lymphocytes, and goes into the blood. CLL is the most common type of leukemia in adults.¹



Key Statistics for CLL

CLL accounts for about one-quarter of the new cases of leukemia each year.¹

The American Cancer Society estimates there will be **21,250 new cases** and about **4,320 deaths from CLL** this year alone.¹

Survey Key Findings

Despite advances in CLL therapy, there is still a significant unmet need. Many individuals living with CLL reported that their quality of life is impacted by side effects from current treatments. Moreover, both caregivers and their loved ones with CLL report concern about the lack of treatment choices if the current treatment stops working.



HCPs

Recognize the need for more treatment choices and better tolerability in later line therapies.

85% of HCPs say more treatment options for relapsed/refractory patients is very or extremely important for CLL treatment

51% of HCPs agree that patients accept the side effects of their treatment because there are limited treatment options for CLL

75% of HCPs agree that there is a need for safer/more tolerable and more durable treatment options for patients beyond first line

78% of HCPs say new third line and beyond treatment options are very or extremely important for CLL treatments



PEOPLE LIVING WITH CLL

Feel there are currently limited treatments options for CLL and express a need for more treatment options with fewer or less severe side effects.

71% are concerned about the lack of other treatment choices if their current treatment stops working

72% accept the side effects of treatment because there are limited treatment options for CLL. "Just a part of having cancer"



CAREGIVERS

Are looking for more options for their loved ones.

72% are concerned about the lack of treatment options should the current medicine stop working

77% report CLL treatment options are limited

81% want a treatment option for CLL with fewer/less severe side effects

Rising to the Challenge to Change the Expectations in CLL

At Lilly, we unite caring with discovery to create medicines that make life better for people. With greater insight into the unmet needs of people living with CLL, we can work together to raise awareness and bring more treatment options that give people living with CLL hope.

We know that new CLL therapies are important throughout the treatment journey, but can be even more impactful at later lines, for relapsed/refractory people with CLL when treatment options are limited.



At Lilly, we are committed to addressing the unmet needs for those living with CLL by providing people with the disease and those who treat them with more options.

REFERENCES

1. American Cancer Society. Key statistics for Chronic Lymphocytic Leukemia. Available at: <https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/about/key-statistics.html>.

